Radiotherapy 3D printing needs standardized quality assurance across institutions
Inter-centre material variability supports shared QA datasets and standardized acceptance criteria for clinical radiotherapy 3D printing.
Inter-centre material variability supports shared QA datasets and standardized acceptance criteria for clinical radiotherapy 3D printing.
Five-year progression-free and overall survival were 55.4% and 64.6%, with metastatic status and histologic response remaining major prognostic factors.
SGRT triggered verification in 15% of head and neck fractions, but almost half of alerts were not confirmed on X-ray imaging.
Dose to neck skin, subcutaneous tissue, and sternocleidomastoid muscle predicted fibrosis burden in nonsurgical head and neck cancer survivors.
Range of motion improved by nearly 29° after revision arthroplasty preceded by 8 Gy, with parallel improvements in pain and function.
Carbon-ion schedules produced similar tumour outcomes, but sacral insufficiency fractures occurred in 47% versus 24% with 4 Gy(RBE) fractions.
Empty-bladder SBRT was feasible in 85% of screened patients, with grade 2 or higher urinary toxicity of 28.1%.
Three-year outcomes numerically favored 50.4 Gy over 60 Gy, while multivariable analysis found no significant survival advantage from either dose.
Grade 2 dermatitis fell from 38.6% to 25.3% with 16-fraction whole-breast radiotherapy plus simultaneous integrated boost.
4DCT ventilation predicted postoperative FEV1, FVC, and DLCO with concordance coefficients of 0.88–0.91 in the LIME trial.
Multimodal CT–MRI perfusion maps matched SPECT better than single-modality methods and reduced high-function lung dose in exploratory planning.
The standardized workflow generated clinically comparable interstitial brachytherapy plans in a median of 10 minutes versus 28 minutes for manual planning.
Two-year local control reached 88%, but median progression-free survival was 5.8 months and systemic treatment changed after 4.4 months.
COMPPARE enrolled 2,524 patients from 51 institutions in 52 months, with Black participation reaching 16% of the cohort.
Poor sleep affected 69% of survivors, while 21.4% screened as high risk for obstructive sleep apnoea.